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Background: Depersonalisation-derealisation disorder (DPRD) is a distressing and impairing condition with a
pathophysiology that is not well understood. Nevertheless, given the growing interest in its pathogenesis, and the
publication of a number of treatment trials, a systematic review of randomised controlled pharmacotherapy and
psychotherapy trials is timely.
Methods: A systematic search of articles on DPRD published from January 1980 to August 2012, using Cochrane
methods, was conducted. All randomised controlled trials (RCTs) of pharmacotherapy, psychotherapy, somatic
interventions and a blend of these modalities for the treatment of depersonalisation disorder were included in the
review. Searches were carried out on multiple databases. The bibliographies of all identified trials were checked for
additional studies and authors were contacted for published trials. No unpublished trials were found and no
restrictions were placed on language and setting. Data extraction sheets were further designed to enter specified
data from each trial and risk of bias information was identified. PRISMA guidelines were also followed to ensure that
our methodology and reporting were comprehensive. Of the unique 1296 papers that were retrieved, four studies
met the inclusion criteria and were reviewed.
Results: Four RCTs (all within the duration of 12 weeks or less) met study criteria and were included (180
participants; age range 18–65 years). The four RCTs included two lamotrigine studies, one fluoxetine study and one
biofeedback study. Evidence for the treatment efficacy of lamotrigine was found in one study (Cambridge
Dissociation Scale, CDC: p < 0.001) with no evidence of effect for lamotrigine in the second study (CDS: p = 0.61 or
Present State Examination: p = 0.17). Fluoxetine and biofeedback were not more efficacious than the control
condition, although there was a trend for fluoxetine to demonstrate greater efficacy in those with comorbid anxiety
disorder. The four studies had 'low' or 'unclear' risk of bias.
Conclusion: The limited data from randomised controlled trials on the pharmacotherapy and psychotherapy of
DPRD demonstrates inconsistent evidence for the efficacy of lamotrigine, and no efficacy for other interventions.
Additional research on this disorder is needed.
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Depersonalisation disorder (DPRD), renamed deperson-
alisation-derealisation disorder in the DSM-5 (Spiegel
et al. 2011), is an alteration in the perception or experi-
ence of the self and the environment. Individuals with de-
personalisation feel uneasily estranged and separated from
their selves (depersonalisation) and their surroundings
(derealisation), experiencing what was also described as a
sense of disembodiment (desomatisation) and a dimin-
ution or loss of emotional reactivity (de-affectualisation)
(American Psychiatric Association 2000; Medford et al.
2005a; Sierra 2009). Depersonalisation occurs as a persist-
ent, pervasive phenomenon, causing subjective distress
and functional impairment (Medford et al. 2005a). De-
personalisation symptoms can occur in many neuro-
logical (e.g. migraine and epilepsy, (Lambert et al.
2005)) and psychiatric conditions (e.g. major depression,
panic disorder, posttraumatic stress disorder, schizo-
phrenia, stress and fatigue, (Medford 2012)), or it may
occur as a primary phenomenon, in which case it is
classified as depersonalisation-derealisation disorder
(Simeon et al. 1997).
DPRD is frequently a chronic disorder, affecting be-
tween 1% and 2.4% of the general population with a gen-
der ratio of about 1:1, although its comorbidity with
depression and anxiety falls between the percentage
ranges of 20–40 (Bebbington et al. 1997; Hunter et al.
2004a; Ross 1991). Depersonalisation and derealisation
symptoms seem to be more common among women
(26.5%) than men (19.5%) (Aderibigbe et al. 2001). It
was estimated in one survey that DPRD occurred in 80%
of psychiatric inpatients and that 12% of them suffered
from a severe form of this condition (Brauer et al. 1970).
Lifetime prevalence of depersonalisation and derealisa-
tion symptoms of 31 and 66% were found in surveys
conducted among non-clinical respondents compared to a
lifetime prevalence of depersonalisation and derealisation
symptoms of 42 to 91% in psychiatric settings (Hunter
et al. 2004b). Severe clinical depersonalisation was identi-
fied among 1.9% of German participants (Michal et al.
2009) and 5% of psychiatric outpatients in New York
(Foote et al. 2006).
Historical reports of the use of barbiturates, amphet-
amines and antipsychotics in the treatment of DPRD do
not suggest any consistent benefit (Ackner 1954; Shorvon
1946). Subsequent single case reports suggest potential ef-
ficacy for a wide variety of treatments including benzodi-
azepines (phenazepam, (Nuller 1982); clonazepam, (Stein
& Uhde 1989)), atypical neuroleptic medications (cloza-
pine, (Nuller 1982)), tricyclic anti-depressants (desipra-
mine, (Noyes et al. 1987)), drugs with serotonergic activity
(fluoxetine, (Fichtner et al. 1992; Ratliff & Kerski 1995);
fluoxetine and buspirone, (Abbas et al. 1995)), SNRIs
(venlafaxine, (Preve et al. 2011)), a combination ofbenzodiazepines and serotonergic activity drugs (citalo-
pram-clonazepam, (Sachdev 2002)), anti-convulsants
(lamotrigine, (Sierra et al. 2006)), (methylphenidate,
(Foguet et al. 2011)), and opiate antagonists (naltrexone,
(Ginsberg 2005)). Other tried psychiatric interventions in-
cluded electroconvulsive therapy (ECT) (Ordas & Ritchie
1994) and transcranial magnetic stimulation (Jimenez-
Genchi 2004). Psychotherapy case reports have indicated
that psychodynamic psychotherapy (Torch 1987) and
hypnosis-based treatment, combined with eye movement
desensitisation and reprocessing (EMDR), (Hollander
2009)), may also be useful.
Several small open-label studies have also been con-
ducted. Based on the hypothesis that emotional numbing
is an opiate-mediated phenomenon, nalmefene, an oral
opiate antagonist, was administered and reported to
lessen depersonalisation symptoms in some combat vet-
erans suffering from PTSD (Glover 1993). Although the
duration of the response was not clearly described, a
marked decline in chronic depersonalisation was reported
in subjects treated intravenously with naloxone, another
opiate antagonist (Nuller et al. 2001). In a later open pro-
spective trial of naltrexone administered to 12 participants
with DPRD who completed at least four weeks of naltrex-
one treatment, four (33%) showed marked improvement
with a 50% to 90% reduction in symptoms (Simeon &
Knutelska 2005).
A different body of research suggests that glutamate
might be relevant to dissociation. Sub-anesthetic doses
of the N-methyl D-aspartate receptor antagonist keta-
mine were shown to induce subjective experiences char-
acteristic of depersonalisation (Krystal et al. 1994). It is
believed that the altered state of consciousness induced
by ketamine is mediated by increased glutamate release
in response to NMDA receptor blockades, with a conse-
quent excess of glutamate activity at non-NMDA glutam-
ate receptors (Abel et al. 2003; Pikwar 2011). Lamotrigine
has been reported in the treatment of DPRD because of
its ability to impede glutamate release at the presynaptic
membrane and to reduce the effects of ketamine on con-
sciousness (Anand et al. 2000; Wang et al. 1996). While a
crossover, double-blind study on nine patients with DPRD,
failed to show any beneficial effects of lamotrigine (Sierra
et al. 2003), lamotrigine was reported to benefit some pa-
tients with chronic DPRD (Sierra et al. 2006; Sierra et al.
2001) when used as an add-on therapy.
There have also been some publications on psycho-
therapy research in DPRD. One psychoanalytic case
study was mentioned earlier (Torch 1987), and two
additional case reports representing behavioral therapy
(Sookman & Solyom 1978) and directive therapy (Blue
1979) have been published. However, the last two re-
ports focused on depersonalisation as a co-morbid,
secondary disorder. A cognitive–behavioral model of
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another potential form of treatment. This model is based
on evidence that depersonalisation is associated with anx-
iety rather than with dissociative conditions (Medford
et al. 2005b; Hunter et al. 2003; Hunter et al. 2005a).
Nevertheless, the disorder remains a poorly under-
stood condition that has received relatively little research
attention. Lack of awareness of DPRD may contribute to
a high rate of misdiagnosis (Hunter et al. 2004a). With
growing interest in the management of DPRD, it is
timely to conduct a systematic review to determine the
efficacy of medication, psychotherapy, somatic interven-
tions and a combination of treatment modalities for
depersonalisation-derealisation disorder, relative to pla-
cebo and other comparison groups.
Methods
Identification of studies
The literature search was carried out using the following
databases: the Cochrane Central Register of Controlled
Trials (CENTRAL) (The Cochrane Library, Issue 8),
MEDLINE, PsycINFO, the metaRegister of Controlled
Trials database (mRCT), the National Institute of Health's
Computer Retrieval of Information on Scientific Projects
(CRISP) service, ClinicalTrials.gov, and the WHO Inter-
national Clinical Trials Registry Platform (ICTRP), for
articles published from January 1980 to August 2012. The
following search terms (in both American and British
English) were used:
“depersonalisation disorder” OR “derealisation disorder”
OR “depersonalisation-derealisation disorder” OR “deper-
sonalisation syndrome” OR “derealisation syndrome” OR
“depersonalisation-derealisation syndrome” AND “drug”
OR “pharmacotherapy” OR “medication” OR “treatment”
AND “randomised control trial” OR “RCT”. The initial
search yielded 1296 studies, of which four met study cri-
teria and were included. The bibliographies of all identi-
fied trials were checked for additional studies and the
authors were contacted for published trials. No restriction
was placed on language and setting. Studies employing
cross-over and parallel designs were potentially considered
for inclusion. No unpublished trials were found.
Criteria for considering studies for this review in-
cluded (a) all randomised controlled trials (RCTs) of
pharmacotherapy, psychotherapy, somatic interventions
and a combination of treatments for depersonalisation dis-
order, (b) all participants diagnosed with depersonalisation
disorder according to the criteria of the Diagnostic and
Statistical Manual (DSM-III-R, (American Psychiatric As-
sociation 1987) or DSM-IV, (American Psychiatric Associ-
ation 1994)), or the International Classification of Diseases
(ICD-9, (National Center for Health Statistics 2002) or
ICD-10, (World Health Organization 2008)) irrespective of
age, in- or outpatient status, or presence of comorbidity,(c) all medication agents and non-pharmacological in-
terventions (e.g. selective serotonin reuptake inhibitors
(SSRIs), anticonvulsants and opiate antagonists, temporo-
parietal junction stimulation), and (d) RCTs of all forms of
psychotherapy (e.g. behavioural modification and cogni-
tive restructuring programs, relaxation, gestalt, interper-
sonal, supportive therapies, mindfulness, acceptance and
commitment therapy, compassion-focused therapy). Both
short- and long-term therapy were eligible for inclusion,
as was group therapy in which cluster randomisation de-
signs were employed.
Where possible, planned treatment comparisons
included:
1. Pharmacotherapy versus placebo.
2. Psychotherapy versus sham interventions or waiting
list.
3. Psychotherapy versus pharmacotherapy.
4. Pharmacotherapy versus non-pharmacological
interventions.
Outcome measures and effect variables
Primary outcomes
Treatment response was reported if studies used the Clin-
ical Global Impressions-Improvement subscale (CGI-I), a
widely used categorical measure of treatment response in
which responders are defined as having a change item
score of 1 = "very much" or 2 = "much" improved (CGI,
(Guy et al. 1976)), or by a 50% reduction reported by the
Cambridge Depersonalization Scale (Sierra & Berrios
2000).
The effect of intervention on symptom severity was
determined from standardised instruments such as the
Cambridge Depersonalisation Scale, the Dissociative Expe-
riences Scale (DES, (Bernstein-Carlson & Putnam 1993)),
or the Depersonalisation Severity Scale (DSS, (Simeon
et al. 2001)).
Secondary outcomes
Depression was reported if studies provided data on the
17-item Hamilton Rating Scale for Depression (HRSD,
(Hamilton 1960)), the Beck Depression Inventory (BDI,
(Beck et al. 1961)), or a similar scale. Anxiety was mea-
sured with the standard Hamilton Rating Scale for Anx-
iety (HRSA, (Hamilton 1959)) the Beck Anxiety Inventory
(BAI, (Beck et al. 1988), or a similar scale. Symptom im-
provement in other anxiety disorders similarly employed
customary “gold-standard” severity measures.
Meta-analysis
The analytical summary of the selected studies was con-
sidered but high heterogeneity across studies prohibited
combining results to produce a single overall estimate of
effect.
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Selection of studies
In order to determine whether studies were eligible for
inclusion, the Cochrane steps of a systematic search
were followed. This entailed the screening of titles and
abstracts for face validity within the selected databases.
Included, excluded and unclear studies were colour
coded, and the full text articles for each study were re-
trieved. After full text screening, studies were further in-
cluded or excluded based on the study criteria for the
review. This process was completed by one of the au-
thors (ES). Spreadsheet forms were designed for the pur-
pose of recording descriptive information, summary
statistics of the outcome measures, risk of bias data, and
associated commentary (ES and TW). The reviewers
contacted investigators by email in an attempt to obtain
missing information. A narration of each trial is provided
in the results section. PRISMA guidelines (Moher et al.
2009) were also followed to ensure that the methodology
and reporting were comprehensive (see Table 1).Results
Results of the search
MEDLINE, ClinicalTrials.gov, WHO trials and PsycINFO
searches retrieved 1147 and 149 unique articles, respect-
ively. The search of the CCDAN Controlled Trials Regis-
try yielded two additional results. Reviews of reference
lists of key studies identified one more study, resulting in
a total of 1296 unique abstracts (see Figure 1). Of the 14
open and cross-over trials, one was a double-blind,
placebo-controlled study that was selected for this review.
Four double-blind, placebo-controlled studies (three ran-
domised and one cross-over) were finally selected for in-
dependent assessment by two raters (ES and DS). No
unpublished trials were found.Description of included studies
The search included four double-blind RCTs of treat-
ment for depersonalisation (180 participants, see Table 2).
A placebo comparison group was employed in each
study and the four studies consisted of one psychother-
apy (biofeedback) and three pharmacotherapy trials (two
lamotrigine and one fluoxetine). Each study was pub-
lished in English and recruited outpatients from single
centres. One trial was funded by the National Institute
of Mental Health (NIMH) (the fluoxetine and placebo
capsules were provided by Eli Lilly) and another by the
Medical Research Council (MRC) (Schoenberg et al. 2012;
Simeon et al. 2004). Countries in which studies were
conducted included the United Kingdom (Schoenberg
et al. 2012; Sierra et al. 2003), the United States of
America (Simeon et al. 2004) and Azerbaijan (Aliyev &
Aliyev 2011).The average sample size was 44 and ranged from 14
(Sierra et al. 2003) to 80 (Aliyev & Aliyev 2011). Three
studies consisted of both males and females, and one
study males only (Aliyev & Aliyev 2011) (mean age for
all four groups: 36 years). Amongst others, common in-
clusions were: adults aged 18–65 years; DSM–IV or PSE
(Sierra et al. 2003) diagnostic criteria for current deper-
sonalisation disorder; and written informed consent. Par-
ticipants were excluded if they had a lifetime diagnosis
of schizophrenia, schizoaffective disorder, bipolar dis-
order, organic mental disorder and substance use dis-
order (Sierra et al. 2003; Schoenberg et al. 2012), eating
disorder, acute or unstable medical illnesses (Simeon
et al. 2004), as well as those with a history of seizure dis-
order or major head trauma. Pregnant and lactating
women were also excluded (Schoenberg et al. 2012).
The duration of treatment for all interventions ranged
between eight sessions of psychotherapy (Schoenberg et al.
2012) to 12 weeks of pharmacotherapy (Sierra et al. 2003;
Aliyev & Aliyev 2011). Dose of medication in the pharma-
cological studies ranged from 10 mg/day (Schoenberg et al.
2012) to 300 mg/day (Simeon et al. 2004). Primary and
secondary outcomes include CDS, DES (Sierra et al. 2003;
Schoenberg et al. 2012; Aliyev & Aliyev 2011), BAI
(Schoenberg et al. 2012) and BDI (Sierra et al. 2003;
Schoenberg et al. 2012), PES, CGI-I, DSS, HRDS, HRSA,
LSAS, YBOCS and DSM-IV (Sierra et al. 2003). Two par-
ticipants (one female and one male) dropped out of the
sham condition in the biofeedback study. No side effects
were reported in this study (Schoenberg et al. 2012). Fif-
teen dropouts were reported (three because of the develop-
ment of a rash in the medication group (Aliyev & Aliyev
2011) compared to five dropouts (Sierra et al. 2003) in two
studies investigating lamotrigine). Seven participants fur-
ther dropped out due to various side effects (i.e. dizziness,
muscle aches, nausea, sedation, fatigue and neutropenia) in
these two studies (Sierra et al. 2003). In addition, thirteen
participants dropped out of the fluoxetine study. Side ef-
fects in at least 10% of the two study groups were reported
in this trial (Simeon et al. 2004).
Description of excluded studies
Sixteen abstracts concerning case and retrospective
studies on the treatment of DPRD were identified but
excluded from this study due to inadequate sample
size and lack of a control group. Described interven-
tions included SSRIs (Hollander et al. 1990), benzodi-
azepines and anti-psychotics (Nuller 1982), an opioid
receptor antagonist (Glover 1993), lamotrigine as a
single (Sierra et al. 2001) or add-on treatment (Sierra
et al. 2006), the opioid receptor antagonists naloxone
(Simeon & Knutelska 2005) and naltrexone (Ginsberg
2005; Simeon & Knutelska 2005). One open label trial
on temporo-parietal junction stimulation (Mantovani
Table 1 PRISMA checklist
Title #
Title 1 A systematic review titled: “Evidence-based Treatment for Depersonalisation-derealisation Disorder (DPRD)”.
Abstract
Structured summary 2 Background
Depersonalisation-derealisation disorder (DPRD) is a distressing and impairing condition with a pathophysiology that is
not well understood.
Objectives
A systematic review of randomised controlled pharmacotherapy and psychotherapy trials.
Data sources
Articles on DPRD published from January 1980 to August 2012. Searches were carried out on The Cochrane Central
Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 8), MEDLINE, PsycINFO, the metaRegister of
Controlled Trials database (mRCT), the National Institute of Health's Computer Retrieval of Information on Scientific
Projects (CRISP) service, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform (ICTRP).
Study eligibility criteria
Randomised controlled trials (RCTs).
Participants
Individuals diagnosed with depersonalisation disorder (i.e. DSM-III-R, DSM-IV, ICD-9 or ICD-10) irrespective of age, in- or
outpatient status, or presence of comorbidity.
Interventions
Pharmacotherapy (e.g. SSRIs), psychotherapy (e.g. behavioural modification and cognitive restructuring programs),
somatic interventions (e.g. health education) and a blend of these modalities.
Study appraisal methods
Data extraction sheets were designed to enter specified data from each trial and risk of bias information was identified.
Results
Four RCTs (all within the duration of 12 weeks or less) met study criteria and were included (180 participants; age
range 18–65 years). The four RCTs included two lamotrigine studies, one fluoxetine study and one biofeedback study.
Evidence for the treatment efficacy of lamotrigine was found in one study (Cambridge Dissociation Scale (CDS): p <
0.001) with no evidence of effect for lamotrigine in the second study (CDS: p = 0.61 or Present State Examination (PSE):
p = 0.17). Fluoxetine and biofeedback were not more efficacious than the control condition, although there was a
trend for fluoxetine to demonstrate greater efficacy in those with comorbid anxiety disorder. The four studies had 'low'
or 'unclear' risk of bias.
Limitations
There are a small number of studies with small samples. There are differences across trials in sample characteristics,
and timing of interventions.
Conclusion
The limited data from randomised controlled trials on the pharmacotherapy and psychotherapy of DPRD demonstrates
inconsistent evidence for the efficacy of lamotrigine, and no efficacy for other interventions. Additional research on this
disorder is needed.
Introduction
Rationale 3 DPRD is not a rare condition. It occurred in 80% of psychiatric inpatients. A lifetime prevalence of depersonalisation
and derealisation symptoms of 42 to 91% was reported in psychiatric settings. Given the growing interest in its
pathogenesis, and the publication of a number of treatment trials, a systematic review of randomised controlled
pharmacotherapy and psychotherapy trials is timely.
Objectives 4 Lack of awareness of DPRD may contribute to a high rate of misdiagnosis. With growing interest in the management
of DPRD, we aimed at conducting a systematic review to determine the efficacy of medication, psychotherapy,
somatic interventions and a combination of treatment modalities for depersonalisation-derealisation disorder, relative
to placebo and other comparison groups.
Methods
Protocol and
registration
5 This systematic search used Cochrane methods (http://www.cochrane.org).
Eligibility criteria 6 RCTs of pharmacotherapy, psychotherapy, somatic interventions and a blend of these modalities for the treatment of
DPRD published from January 1980 to August 2012 in any language.
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Information sources 7 Searches were carried out on The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue
8), MEDLINE, PsycINFO, the metaRegister of Controlled Trials database (mRCT), the National Institute of Health's
Computer Retrieval of Information on Scientific Projects (CRISP) service, ClinicalTrials.gov, and the WHO International
Clinical Trials Registry Platform (ICTRP). The bibliographies of all identified trials were checked for additional studies and
authors were contacted for published trials.
Search 8 For each database, the following search terms (in both American and British English) were used: “depersonalisation
disorder” OR “derealisation disorder” OR “depersonalisation-derealisation disorder”, OR “depersonalisation syndrome” OR
“derealisation syndrome” OR “depersonalisation-derealisation syndrome”, AND “drug” OR “pharmacotherapy” OR
“medication” OR “treatment” OR “psychotherapy”, AND “randomised control trial”, OR “RCT”. The bibliographies of all
identified trials were checked for additional studies and the authors were contacted for published trials. No restriction
was placed on language and setting. Studies employing cross-over and parallel designs were potentially considered for
inclusion.
Study selection 9 The criteria for selecting studies included (a) all RCTs of pharmacotherapy, psychotherapy, somatic interventions and a
combination of treatments for DPRD, (b) all participants diagnosed with DPRD irrespective of age, in- or outpatient
status, or presence of comorbidity, (c) all medication agents and non-pharmacological interventions, and (d) RCTs of all
forms of psychotherapy. Both short- and long-term therapy were eligible for inclusion, as was group therapy in which
cluster randomization designs were employed. Titles and abstracts were screened for face validity within the selected
databases. Included, excluded and unclear studies were color coded, and the full text articles for each study were
retrieved. After full text screening, studies were further included or excluded based on the study criteria for the review.
Data collection
process
10 Study selection was completed by one of the authors (ES). Spreadsheet forms were designed for the purpose of
recording descriptive information, summary statistics of the outcome measures, risk of bias data, and associated
commentary (ES and TW). The reviewers contacted investigators by email in an attempt to obtain missing information.
PRISMA guidelines were also followed to ensure that the methodology and reporting were comprehensive.
Data items 11 Aliyev and Aliyev 2011; Sierra et al. 2003; Simeon et al. 2004 and Schoenberg et al. 2012
Participants
All participants diagnosed with depersonalisation disorder according to the criteria of the Diagnostic and Statistical
Manual (DSM-III-R or DSM-IV), or the International Classification of Diseases (ICD-9 or ICD-10) irrespective of age, in- or
outpatient status, or presence of comorbidity.
Interventions
All medication agents and non-pharmacological interventions (e.g. selective serotonin reuptake inhibitors (SSRIs),
anticonvulsants and opiate antagonists, temporo-parietal junction stimulation), and RCTs of all forms of psychotherapy
(e.g. behavioural modification and cognitive restructuring programs, relaxation, gestalt, interpersonal, supportive
therapies, mindfulness, acceptance and commitment therapy, compassion-focused therapy). Both short- and long-term
therapy were eligible for inclusion, as was group therapy in which cluster randomisation designs were employed.
Comparisons
Where possible, planned treatment comparisons included:
1. Pharmacotherapy versus placebo.
2. Psychotherapy versus sham interventions or waiting list.
3. Psychotherapy versus pharmacotherapy.
4. Pharmacotherapy versus non-pharmacological interventions.
Outcomes
Diagnostics & baseline screening: all participants diagnosed with depersonalisation disorder according to the criteria of
the Diagnostic and Statistical Manual (DSM-III-R, or DSM-IV), or the International Classification of Diseases (ICD-9, or
ICD-10).
Primary measures: Treatment response was reported if studies used the Clinical Global Impressions-Improvement
subscale (CGI-I), a widely used categorical measure of treatment response in which responders are defined as having a
change item score of 1 = "very much" or 2 = "much" improved (CGI), or by a 50% reduction reported by the
Cambridge Depersonalization Scale. The effect of intervention on symptom severity was determined from standardised
instruments such as the Cambridge Depersonalisation Scale, the Dissociative Experiences Scale (DES), or the
Depersonalisation Severity Scale (DSS).
Secondary measures: Depression was reported if studies provided data on the 17-item Hamilton Rating Scale for
Depression (HRSD), the Beck Depression Inventory (BDI), or a similar scale. Anxiety was measured with the standard
Hamilton Rating Scale for Anxiety (HRSA) the Beck Anxiety Inventory (BAI, or a similar scale. Symptom improvement in
other anxiety disorders similarly employed customary “gold-standard” severity measures.
Risk of bias in
individual studies
12 The overall risk of bias was evaluated as ‘high’, ‘low’ or ‘unclear’ according to the five criteria stipulated by the
Cochrane Handbook for Systematic Reviews of Interventions: random sequence generation, allocation concealment,
blinding (performance bias and detection bias), blinding of outcome assessment, incomplete outcome data (attrition
bias), and selective reporting (reporting bias).
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Summary measures 13 Treatment response was reported if studies used the Clinical Global Impressions-Improvement subscale (CGI-I), a
measure of treatment response in which responders are defined as having a change item score of 1 = "very much" or
2 = "much" improved (CGI), or by a 50% reduction reported by the Cambridge Depersonalization Scale (CDS). The
effect of intervention on symptom severity was determined from standardized instruments such as the CDS, the
Dissociative Experiences Scale (DES), or the Depersonalization Severity Scale.
Synthesis of results 14 Due to the clinically diverse nature of each trial, with different interventions used in different studies, the trials could
not be meta-analysed.
Risk of bias across
studies
15 All four studies were rated as having an “unclear” risk of bias for selective reporting, because there was no protocol
available to determine if all outcomes were measured.
Additional analyses 16 N/A.
Results
Study selection 17 Records identified through database searching: n = 1296; Records excluded: n = 237, Reason: Duplicates; Title screening:
n = 1059; Records excluded: n = 341, Reason: Not Depersonalisation/derealisation; Abstract screening: n = 718; Records
excluded: n = 689, Reason: Not treatment articles or no outcome provided; Full-text articles assessed for eligibility: n =
29; Full-text articles excluded: n = 25, Reasons: Retrospective studies and open trials; Studies included in qualitative
synthesis: n = 4.
Study characteristics 18 Medication
● Aiyev 2011: Azerbaijani outpatients, single center, lamotrigine (25–300 mg/day), placebo comparison, 12 weeks, 80
randomised, mean age 37.7; 0% female, diagnostics: CDS.
● Sierra et al. 2003: UK outpatients, single center, Lamotrigine (25–250 mg/day), placebo comparison, 12 weeks, 14
randomised, mean age 35.2, diagnostics: DSM-IV, PSE, CDS.
● Simeon 2004: USA outpatients, single center, Fluoxetine (10–60 mg/day Eli Lilly); placebo comparison, 10 weeks, 54
randomised, mean age 36, 39% female, diagnostics: SCID-D.
Psychotherapy
● Schoenberg et al. 2012: UK outpatients, single center, electro-dermal biofeedback, sham electro-dermal biofeedback,
4 weeks (8 sessions), 32 randomised, mean age 35, 25% female, diagnostics: SCID-D.
Risk of bias within
studies
19 Medication
● Aliyev and Aliyev 2011: random sequence generation - low; allocation concealment - low; blinding (performance
bias and detection bias) - low; blinding of outcome assessment - low; incomplete outcome data - low; selective
outcome reporting - unclear.
● Sierra et al. 2003: random sequence generation - low; allocation concealment - low; blinding (performance bias and
detection bias) - unclear; blinding of outcome assessment - low; incomplete outcome data - low; selective outcome
reporting - unclear.
● Simeon et al. 2004: random sequence generation - low; allocation concealment - low; blinding (performance bias
and detection bias) - unclear; blinding of outcome assessment - low; incomplete outcome data - low; selective
outcome reporting - unclear.
Psychotherapy
● Schoenberg et al. 2012: random sequence generation - unclear; allocation concealment - low; blinding (performance
bias and detection bias) - low; blinding of outcome assessment - low; incomplete outcome data - low; selective
outcome reporting - unclear.
Results of individual
studies
20 Medication
● Simeon et al. 2004: Fluoxetine was not superior to placebo except for a clinically minimal but statistically significantly
greater improvement in CGI–I score in the fluoxetine group. In participants with a comorbid diagnosis of depressive or
anxiety disorder, those taking fluoxetine consistently tended to have better responses than those taking the placebo.
● Sierra et al. 2003: A cross-over study among nine individuals suffering from DPRD comparing the lamotrigine with a
placebo revealed following a 2-week washout that lamotrigine had no significant advantage over placebo when
administered singularly for DPRD.
● Aliyev and Aliyev 2011: 12 weeks of lamotrigine therapy resulted in a statistically significant difference in
improvement in a lamotrigine group compared with that in the placebo group.
Psychotherapy
● Schoenberg 2012: While electro-dermal biofeedback did not help DPRD participants increase skin conductance
response, real-time biofeedback resulted in lower state (but not trait) scores on the CDS. Biofeedback had no effect on
DES, BDI or BAI scores, compared to sham biofeedback.
Synthesis of results 21 N/A
Risk of bias across
results
22 There was no protocol available to determine if all outcomes were measured in the four selected studies. Risk of bias
for selective reporting were rated as “unclear” for all included studies.
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Table 1 PRISMA checklist (Continued)
Additional analyses 23 N/A
Discussion
Summary of evidence 24 Data on lamotrigine for DPRD was inconsistent with one trial indicating that lamotrigine was not significantly better
than placebo when applied as a singular treatment for DPRD, and one trial showing a statistically significant difference
in improvement compared placebo. Fluoxetine was not demonstrated to be efficacious in treating depersonalization
disorder. However, there was a tendency for depersonalization symptoms to improve in subjects with a comorbid
anxiety disorder. Electro-dermal biofeedback was not effective in increasing SCR (a marker of emotional response) or in
decreasing trait measures of depersonalization. However, SCR biofeedback did result in lower state scores on the CDS.
Limitations 25 We identified a small number of studies with small samples. There are differences across trials in sample characteristics
and timing of interventions. Although we used a rigorous search methodology, we may have missed unpublished
trials; there is, for example, a bias against the publication of negative studies.
Conclusions 26 There is inconsistent evidence to support the efficacy of lamotrigine in DPRD, with no evidence to support the efficacy
of fluoxetine and biofeedback. Further research is necessary, particularly in light of the methodological differences
between studies.
Funding
Funding 27 No funding was available for this review.
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et al. 2005b) was also excluded.
Risk of bias within studies
The overall risk of bias was evaluated as ‘high’, ‘low’ or
‘unclear’ according to the five criteria stipulated by theIdentification
Records exclu
Reason: Dupli
Records identified 
through database 
searching:  n=1296
Record
Reason
Included
Studies included in 
qualitative synthesis: n=4
Screening
Full-text articles assessed 
for eligibility: n=29
Eligibility
Abstract screening: n=718
Title screening: n= 1059
Full-text 
Reasons: 
Records exclu
Reason:  Not 
Figure 1 Flow of information through the different phases of the sysCochrane Handbook for Systematic Reviews of Interven-
tions (Higgins & Green 2008): random sequence gener-
ation, allocation concealment, blinding (performance
bias and detection bias), blinding of outcome assess-
ment, incomplete outcome data (attrition bias), and se-
lective reporting (reporting bias) (see Table 3).ded: n=237
cates
s excluded: n=341
: Not Depersonalisation/derealisation
articles excluded: n=25
 Retrospective studies and open trials 
ded: n=689
treatment articles or no outcome provided
temic review.
Table 2 Randomized controlled trials included in the review (n = 4)
Study ID Funding Country &
Setting
Intervention Comparison Weeks
(sessions)
Total
randomised
Mean
age of
sample
% female
in sample
Diagnostics
& baseline
screening
Primary
measures
Secondary
measures
Drop-
outs
Lost to
follow-up
Medication
Aliyev and
Aliyev 2011
None Azerbaijan
outpatients
(single centre)
Lamotrigine (dose:
25–300 mg/day)
Placebo 12 80 37.7 0 CDS CDS Improvement 15 -
Sierra et al.
2003
None UK outpatients
(single centre)
Lamotrigine (dose:
25–250 mg/day)
Placebo 12 14 35.2 DSM-IV PSE DES 5 -
PSE CDS BDI
CDS
Simeon
et al. 2004
NIMH grant USA
outpatients
(single centre)
Fluoxetine (dose:
10–60 mg/day)
(provided by Eli Lilly)
Placebo 10 54 36 39 SCID-D CGI-I HRSA 13 -
Semi-structured
clinical interview
DES-DP HRSD
DSS LSAS
YBOCS
Panic attacks
Psychotherapy
Schoenberg
et al. 2012
Medical
Research
Council
UK outpatient
(single centre)
Electro-dermal
biofeedback
(8 sessions)
Sham electro-
dermal
biofeedback
4 (8) 32 35 25 SCID-D CDS - 2 -
DES
BAI
Pilkington
Pilozzo
Charitable Trust
BDI
Som
er
et
al.BM
C
Psychology
2013,1:20
Page
9
of
13
http://w
w
w
.biom
edcentral.com
//1/1/20
Table 3 Risk of bias in selected studies
Study ID 1 2 3 4 5 6
Pharmacotherapy
Aliyev and Aliyev 2011 Low Low Low Low Low Unclear
Sierra et al. 2003 Low Low Unclear Low Low Unclear
Simeon et al. 2004 Low Low Unclear Low Low Unclear
Psychotherapy
Schoenberg et al. 2012 Unclear Low Low Low Low Unclear
1: random sequence generation; 2: allocation concealment; 3: blinding
(performance bias and detection bias); 4: blinding of outcome assessment;
5: incomplete outcome data; 6: selective outcome reporting.
Somer et al. BMC Psychology 2013, 1:20 Page 10 of 13
http://www.biomedcentral.com//1/1/20Random sequence generation
Three trials were rated as having a “low” risk of bias on
the basis of random sequence generation (i.e. use of a
randomisation table, list or code) (Sierra et al. 2003;
Simeon et al. 2004; Aliyev & Aliyev 2011). One trial was
rated “unclear” (Schoenberg et al. 2012), as the trial indi-
cated that the participants were randomised however the
procedure was not clearly defined.
Allocation concealment
All four studies were rated as having a ‘low’ risk of bias
on the basis of allocation concealment. The pharmaco-
logical studies all used identical appearing capsules for
the medication and placebo groups (Sierra et al. 2003;
Simeon et al. 2004; Aliyev & Aliyev 2011). For the psy-
chotherapy study, biofeedback and sham was presented
on an identical interface (Schoenberg et al. 2012).
Blinding of participants, assessors and personnel
Two trials were rated as having a ‘low’ risk for perform-
ance and detection bias. In the first trial both the patient
and the treating psychiatrist were blinded to treatment
(Aliyev & Aliyev 2011), whereas the second study was
patient blind (Schoenberg et al. 2012). The additional
two trials were rated ‘unclear’ (Sierra et al. 2003; Simeon
et al. 2004), as they did not provide evidence to deter-
mine if blinding occurred.
Blinding of outcome assessment
Each trial was rated as having a “low” risk of bias on the
basis of blinding of the outcome assessment. For the
biofeedback group procedures were identical to those in
experimental group (Schoenberg et al. 2012). There was
no clear need for the outcome assessments to be blind
in the additional three trials (Sierra et al. 2003; Simeon
et al. 2004; Aliyev & Aliyev 2011).
Incomplete outcome data (attrition bias)
All four studies were rated “low” for attrition bias be-
cause all outcomes were reported on. For two studies,
dropouts were excluded from the analysis, with no rea-
sons given for dropouts (Sierra et al. 2003; Aliyev &Aliyev 2011). No baseline scores were reported on in
one study using lamotrigine (Aliyev & Aliyev 2011).
Selective reporting (reporting bias)
For selective reporting, all four studies were rated as hav-
ing an “unclear” risk of bias, because there was no proto-
col available to determine if all outcomes were measured.
Other biases
All four studies were posed with several limitations. In
the biofeedback study (Schoenberg et al. 2012), half the
patients (17 participants) were on various medications
which may have affected autonomic response; however,
the two conditions were similar in terms of the ratio be-
tween medicated and non-medicated patients, and medi-
cation status was not a significant confound. There was
a preponderance of men in the DPRD group compared
to the control group, but significant between-group ef-
fects were still evident after covarying for age and sex.
Only thirty two participants were randomised, this is
small in comparison to other clinical trials. Finally, the
experimenter was not blind to patient allocation; it is
theoretically possible that results were affected by indir-
ectly expressed indicants as to the treatment condition.
This study was also implemented over four weeks which
may have been short for evidence of an effect.
The two studies investigating lamotrigine also had
important limitations. The first study (Aliyev & Aliyev
2011) consisted of eighty men, but no female participants,
so preventing generalisation of results to women. Some pa-
tients were also allowed to take clonazepam for insomnia
and hydroxyzine for the treatment of a rash in concurrent
with lamotrigine. Furthermore, the study only reported on
those participants who completed the study. The second
study (Sierra et al. 2003) used both males and females in
their analysis, but only fourteen participants were rando-
mised over twelve weeks, and dropout rates were high.
In the SSRI study (Simeon et al. 2004), fifty-four pa-
tients were treated over ten weeks with 10-60 mg of
fluoxetine or matching placebo. Some participants were
treated with psychotherapy (e.g. cognitive behavioral
therapy) for three months, and were nevertheless in-
cluded in the analysis. Intention-to-treat analysis was
used, with last observation carried forward for those par-
ticipants who did not complete the study. This study was
also characterised by high withdrawal rates. Well-validated
measures were used and the independent evaluator was
masked to side effects and medication adjustment.
Effects of interventions
Pharmacotherapy versus placebo
Fluoxetine (dose 10-60 mg/day) was not superior to pla-
cebo on three primary outcome measures, except for a
clinically minimal but statistically significantly greater
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vs. 3.6) (Simeon et al. 2004). In participants with a comor-
bid diagnosis of depressive or anxiety disorder, those tak-
ing fluoxetine consistently tended to have better responses
than those taking the placebo (Simeon et al. 2004).
A 12-week double-blind, placebo-controlled, cross-
over study among nine individuals suffering from DPRD,
comparing the anticonvulsive lamotrigine (dose 25-250
mg/day) (Sierra et al. 2003) with a placebo, revealed
following a 2-week washout that lamotrigine had no sig-
nificant advantage over placebo when administered sin-
gularly for DPRD as none of the participants was
identified as a responder to the lamotrigine arm of the
cross-over. Subsequently, 12 weeks of lamotrigine ther-
apy (25–300 mg/day) resulted in a statistically significant
difference in improvement (defined as a 50% reduction
in the Cambridge Depersonalisation Scale) in the lamo-
trigine group compared with that in the placebo group
((Aliyev & Aliyev 2011); ×2 = 22.68, df = 1, p < 0.001).
Psychotherapy versus sham psychotherapy
While electrodermal biofeedback did not help DPRD
participants increase skin conductance response (an
hypothesised index of emotional responsiveness), real-
time biofeedback resulted in lower state (but not trait)
scores on the Cambridge Depersonalisation Scale [early vs.
late mean scores and standard deviations in the real-time
biofeedback group: 36.0 (16.9) vs. 29.9 (18.9), p = 0.01;
compared to 30.5 (14.7) vs. 31.8 (14.9), p = 0.63], scores ob-
tained from patients exposed to sham biofeedback. Bio-
feedback had no effect on DES, BDI or BAI scores,
compared to sham biofeedback.
Meta-analysis
Due to the clinically diverse nature of each trial, with
different interventions used in different studies, the trials
could not be meta-analysed.
Discussion
To the best of our knowledge, this is the first systematic
literature review on the treatment of depersonalisation-
derealisation disorder. Four RCTs (all within the duration
of 12 weeks or less) were found and included in the study
(180 participants; age range 18–65 years). These four
RCTs included one psychotherapy (i.e. biofeedback) and
three pharmacotherapy (i.e. two lamotrigine and two flu-
oxetine) trials, with comparison groups.
Data on lamotrigine for DPRD was inconsistent with one
trial indicating that lamotrigine was not significantly better
than placebo when applied as a singular treatment for
DPRD, and one trial showing a statistically significant dif-
ference in improvement (i.e., 50% reduction in the CDS)
compared placebo (Aliyev & Aliyev 2011). Fluoxetine
was not demonstrated to be efficacious in treatingdepersonalisation disorder. However, there was a tendency
for depersonalisation symptoms to improve in subjects
with a comorbid anxiety disorder (Simeon et al. 2004).
Finally, electrodermal biofeedback was not effective in in-
creasing SCR (a physiological marker of emotional re-
sponse) or in decreasing trait measures of depersonalization
(CDS). However, SCR biofeedback did result in lower state
scores on the CDS.
The RCTs included here demonstrated 'low' or 'un-
clear' risk of bias. Three studies provided evidence for
random generation sequence (Sierra et al. 2003; Simeon
et al. 2004; Aliyev & Aliyev 2011), four for allocation
concealment, two for blinding (Schoenberg et al. 2012;
Aliyev & Aliyev 2011), and all four for incomplete out-
come data; consistent with ratings of a “low” risk of bias.
All four studies had missing study protocols so selective
reporting could not be assessed; this is consistent with
an 'unclear' risk of bias (see Table 3).
The literature has shown that depersonalisation symp-
toms can be induced by serotonin receptor agonists such
as meta-chlorophenylpiperazine (Simeon et al. 1995),
and by substances which act as serotonin agonists such
as cannabis (Shorvon 1946), lysergic acid diethylamide,
and “ecstasy” (McGuire et al. 1994). Serotonin reuptake
inhibitors (SSRIs) were reported to be associated with
positive treatment outcome in eight individuals with
DPRD and comorbid obsessive-compulsive and panic
disorders in a case series (McGuire et al. 1994). Further-
more, in a double-blind crossover trial consisting of
eight weeks of desipramine and eight weeks of clomipra-
mine, there was limited evidence that clomipramine was
more efficacious than desipramine. Nevertheless, in the
only randomized controlled trial of a SSRI in DPRD, flu-
oxetine was not found efficacious.
It is important to recognise the limitations of the exist-
ing literature. There are a small number of studies, each
of which has a relatively small sample size. In addition,
there are differences across trials in sample characteris-
tics, and duration of the interventions. Finally, although
we used a rigorous search methodology, we may have
missed unpublished trials; there is, for example, a bias
against the publication of negative studies.
Given the limited data available, there is arguably a
need for additional research on lamotrigine, other anti-
convulsants, SSRIs, opiate antagonists, and repetitive
transcranial magnetic stimulation (rTMS).
Conclusion
There is inconsistent evidence to support the efficacy of
lamotrigine in DPRD, with no evidence to support the
efficacy of fluoxetine and biofeedback. Given the limited
data available, further exploration of lamotrigine, other
anticonvulsants, SSRIs, opiate antagonists, and repetitive
transcranial magnetic stimulation (rTMS) in larger trials
Somer et al. BMC Psychology 2013, 1:20 Page 12 of 13
http://www.biomedcentral.com//1/1/20may be useful. Indeed, a great deal of further research
on the pathogenesis and treatment of depersonalisation-
derealisation disorder is required.
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